FLT3 and hematologic disorder: Section 10 (Synergistic Effects and Combination Therapies): This section highlights OC’s significant potential in combination therapies, detailing its synergistic interactions with standard treatments (e.g., PARP inhibitors, taxanes, FLT3 inhibitors) across various cancers, including prostate, pancreatic, glioblastoma, and hematological malignancies, by mitigating chemoresistance and toxicity.